Darmiyan’s virtual microscope BrainSee has achieved high performance accuracy and consistency in measuring Alzheimer’s-related abnormalities in a new study.

The study was aimed at validating the device in predicting the cognitive future (prognosis) of mild cognitive impairment patients in the actual clinical setting.

BrainSee is a software as a service (SaaS) platform, which analyses standard clinical brain MRI scans. It provides detailed brain maps with precise quantification of neurodegeneration in each voxel and to predict the possibility of future cognitive decline.

The study found that BrainSee performs with as high accuracy on clinical-grade data as it had previously performed on research-grade data. 107 new patients were blind-tested in the current third-party validation study.

Earlier, a blind retrospective analysis was conducted on 411 amnestic mild cognitive impairment (aMCI) patients with research-grade input data. It reported more than 90% performance accuracy.

As part of the study, a separate analysis was organised for evaluating BrainSee’s test-retest reliability on 84 additional aMCI patients. These patients underwent one clinical-grade and one research-grade MRI scans on the same day.

The test-retest consistency of BrainSee was found to be very high with a correlation coefficient of 99.5%.

Darmiyan chief medical and technology officer Kaveh Vejdani said: “While reading brain PET scans at Stanford and NYU hospitals as a radiologist, I imagined the day when we could help clinicians visualise and evaluate brain health more comprehensively and objectively while posing less discomfort to patients.

“That day has come now and Darmiyan’s BrainSee technology can finally bring clarity to the field of Alzheimer’s through visualising brain tissue microstructure for doctors. Darmiyan’s Virtual Microscope technology unlocks the enormous informative potential of the currently underutilised brain MRI scans.”

The current study was conducted by third-party investigators from Stanford University, Baycrest Institute, Huntington Medical Research Institutes (HMRI), University Health Network (UHN), Knight Alzheimer’s Disease Research Center (ADRC) at Washington University and GERAS Hamilton Health Sciences (HHS).

The Canadian trial sites were coordinated by Centre for Aging & Brain Health Innovation (CABHI) as part of an Industry Innovation Partnership Programme grant that was awarded to Darmiyan in 2018.